Congress funds Lyme disease innovation race with $5M prize pot
H.R. 7482 — LymeX Authorization Act · Filed by Chris Smith (R-NJ) · 3 cosponsors · Introduced Feb 11, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes the Secretary of Health and Human Services to spend up to $5 million on prize competitions designed to spur innovation in Lyme disease prevention, diagnosis, and treatment. The competitions would engage academia, nonprofits, businesses, and entrepreneurs to develop faster diagnostics and improve patient care.
Why we flagged it
The bill's operative mechanism is a straightforward appropriation to fund prize competitions under an existing statutory framework (Stevenson-Wydler Act). It is a targeted public-health measure with no hidden provisions or narrow carve-outs.
What the text implies
- Prize competitions may incentivize development of diagnostics or treatments that are profitable but not necessarily accessible to low-income or uninsured Lyme disease patients; public funding accelerates private innovation without guaranteeing affordability or equitable access.
- The bill does not specify IP ownership, licensing terms, or public-health safeguards; winning innovations could be patented and priced at market rates, limiting downstream public benefit.
The full analysis lists 3 implications of this text.
Who stands to gain
biotechnology and diagnostics companies; pharmaceutical firms developing Lyme disease treatments; academic research institutions